Completed

Comparing Safety and Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Indinavir sulfate

+ Lamivudine

+ Zidovudine

Drug
Who is being recruted

Blood-Borne Infections+11

+ Urogenital Diseases

+ Genital Diseases

From 13 to 60 Years
+12 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 3
Interventional
See protocol details

Summary

Principal SponsorDupont Merck
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner

This study focuses on HIV-infected individuals, aiming to compare the safety and effectiveness of three different anti-HIV drug combinations. The first combination is efavirenz (DMP 266) plus indinavir, the second is DMP 266 plus zidovudine (ZDV) plus lamivudine (3TC), and the third is indinavir plus ZDV plus 3TC. The importance of this study lies in its potential to identify which drug combination offers the best treatment for HIV, contributing to improved care for those living with this condition.

NCT00002410
Principal SponsorDupont Merck
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 13 to 60 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Blood-Borne InfectionsUrogenital DiseasesGenital DiseasesCommunicable DiseasesImmunologic Deficiency SyndromesImmune System DiseasesInfectionsRetroviridae InfectionsRNA Virus InfectionsSexually Transmitted DiseasesVirus DiseasesSexually Transmitted Diseases, ViralLentivirus InfectionsHIV Infections

Criteria

4 inclusion criteria required to participate
Be post-pubescent
Have CD4 counts greater than or equal to 50 cell/mm3
Have a diagnosis of HIV infection
Have a life expectancy greater than or equal to 12 months
8 exclusion criteria prevent from participating
Concomitant systemic therapy for acute opportunistic infection or malignancy
Ketoconazole, itraconazole, and clarithromycin
Life expectancy less than 12 months
Prior antiretroviral agent within 14 days of initiating study treatment
Show More Criteria

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 41 locations

Phoenix Body Positive

Phoenix, United StatesOpen Phoenix Body Positive in Google Maps

Arizona Clinical Research Ctr Inc

Tucson, United States

Richard Stryker

Beverly Hills, United States

Paul Cimoch

Irvine, United States
Completed41 Study Centers